Why Do We Need Another Antiemetic? Just Ask.
- 15 November 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (22) , 4077-4080
- https://doi.org/10.1200/jco.2003.07.968
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based ChemotherapyJournal of Clinical Oncology, 2003
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomitingCancer, 2003
- Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemeticsCancer, 2003
- Prevention of Cisplatin-Induced Emesis by a Neurokinin-1–Receptor AntagonistNew England Journal of Medicine, 1999
- Can the Placebo Be the Cure?Science, 1999
- Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor AntagonistNew England Journal of Medicine, 1999
- On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993Annals of Oncology, 1996
- On the receiving end—patient perception of the side-effects of cancer chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1983
- Behavioral Treatment for the Anticipatory Nausea and Vomiting Induced by Cancer ChemotherapyNew England Journal of Medicine, 1982